Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 26 articles: HTML format

Single Articles

May 2026
1. MOON AM, Yanagihara TK, Dawson LA, Yu JI, et al
   Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort.
   J Clin Oncol. 2026 May 15:JCO2502399. doi: 10.1200/JCO-25-02399.
   PubMed     Abstract available
   
   
   
2. DUTTA SW, Ali N, Patel PR, Offerman S, et al
   Bridging the Gap: Integrating External Beam Radiation Therapy Into the Management of Hepatocellular Carcinoma.
   J Clin Oncol. 2026 May 15:JCO2600521. doi: 10.1200/JCO-26-00521.
   PubMed    
   
   
   April 2026
3. GELLI M, Ewald J, Tanguy ML, Passot G, et al
   Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial.
   J Clin Oncol. 2026 Apr 22:JCO2501737. doi: 10.1200/JCO-25-01737.
   PubMed     Abstract available
   
   
   February 2026
4. ZHU HD, Fan WJ, Zhao C, Wang S, et al
   Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.
   J Clin Oncol. 2026 Feb 24:JCO2501796. doi: 10.1200/JCO-25-01796.
   PubMed     Abstract available
   
   
   January 2026
5. KANEMITSU Y, Shimizu Y, Mizusawa J, Inaba Y, et al
   Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603.
   J Clin Oncol. 2026 Jan 21:JCO2501231. doi: 10.1200/JCO-25-01231.
   PubMed     Abstract available
   
   
   December 2025
6. KAWAGUCHI Y, Kashiwabara K, Matsuyama Y, Kokudo N, et al
   Reply to: "Revisiting Methodologic Paradigms in Local Therapies for Hepatocellular Carcinoma: Insights From the SURF Study" and "Methodologic and Reporting Gaps in the SURF Trial".
   J Clin Oncol. 2025 Dec 19:JCO2502390. doi: 10.1200/JCO-25-02390.
   PubMed    
   
   
   
7. VITALE A, Mansournia MA, Ponziani FR, Rovetta A, et al
   Revisiting Methodologic Paradigms in Local Therapies for Hepatocellular Carcinoma: Insights From the SURF Study.
   J Clin Oncol. 2025 Dec 19:JCO2501536. doi: 10.1200/JCO-25-01536.
   PubMed    
   
   
   October 2025
8. FRANSSEN S, Rousian M, Filipe WF, Buisman FE, et al
   Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma-PUMP-2 Trial.
   J Clin Oncol. 2025 Oct 13:JCO2500923. doi: 10.1200/JCO-25-00923.
   PubMed     Abstract available
   
   
   June 2025
9. KAWAGUCHI Y, Hasegawa K, Kashiwabara K, Okamura Y, et al
   Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial).
   J Clin Oncol. 2025 Jun 24:JCO2402030. doi: 10.1200/JCO-24-02030.
   PubMed     Abstract available
   
   
   March 2025
10. XI M, Fu Y, Zhang Y
    Reply to: Importance of Defining Recurrence in Hepatocellular Carcinoma: Local or Both Local and Other Intrahepatic Recurrences?
    J Clin Oncol. 2025 Mar 25:JCO2500327. doi: 10.1200/JCO-25-00327.
    PubMed    
    
    
    
11. KIBE Y
    Importance of Defining Recurrence in Hepatocellular Carcinoma: Local or Both Local and Other Intrahepatic Recurrences?
    J Clin Oncol. 2025 Mar 25:JCO2402861. doi: 10.1200/JCO-24-02861.
    PubMed    
    
    
    February 2025
12. FU Y, Zhang Y, Hu D, Zhou Z, et al
    Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?
    J Clin Oncol. 2025 Feb 25:JCO2402615. doi: 10.1200/JCO-24-02615.
    PubMed    
    
    
    
13. NEWMAN NB, Court CM, Parikh AA
    What Is the Optimal Locoregional Approach for Recurrent Hepatocellular Carcinoma?
    J Clin Oncol. 2025 Feb 11:JCO2402541. doi: 10.1200/JCO-24-02541.
    PubMed     Abstract available
    
    
    December 2024
14. XI M, Yang Z, Hu L, Fu Y, et al
    Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial.
    J Clin Oncol. 2024 Dec 18:JCO2401532. doi: 10.1200/JCO-24-01532.
    PubMed     Abstract available
    
    
    
15. MAGYAR CTJ, O'Kane GM, Aceituno L, Li Z, et al
    Liver Transplantation for Hepatocellular Carcinoma: An Expanding Cornerstone of Care in the Era of Immunotherapy.
    J Clin Oncol. 2024 Dec 16:JCO2400857. doi: 10.1200/JCO.24.00857.
    PubMed     Abstract available
    
    
    October 2024
16. 
    Erratum: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguan
    J Clin Oncol. 2024 Oct 10:JCO2402040. doi: 10.1200/JCO-24-02040.
    PubMed    
    
    
    August 2024
17. SHEN YC, Liu TH, Nicholas A, Soyama A, et al
    Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.
    J Clin Oncol. 2024 Aug 28:JCO2400645. doi: 10.1200/JCO.24.00645.
    PubMed     Abstract available
    
    
    July 2024
18. JAIN A, Lau NS
    Liver Transplantation in Colorectal Cancer With Unresectable Liver Metastases: Disease Biology Cannot Be Ignored.
    J Clin Oncol. 2024 Jul 8:JCO2400619. doi: 10.1200/JCO.24.00619.
    PubMed    
    
    
    June 2024
19. ETTRICH TJ, Modest DP, Sinn M, Striefler JK, et al
    Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).
    J Clin Oncol. 2024 Jun 6:JCO2301566. doi: 10.1200/JCO.23.01566.
    PubMed     Abstract available
    
    
    
20. KAWAZOE A, Xu RH, Garcia-Alfonso P, Passhak M, et al
    Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
    J Clin Oncol. 2024 Jun 4:JCO2302736. doi: 10.1200/JCO.23.02736.
    PubMed     Abstract available
    
    
    May 2024
21. SANGRO B, Galle PR, Kelley RK, Charoentum C, et al
    Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.
    J Clin Oncol. 2024 May 28:JCO2301462. doi: 10.1200/JCO.23.01462.
    PubMed     Abstract available
    
    
    
22. FICHTINGER RS, Aldrighetti LA, Abu Hilal M, Troisi RI, et al
    Laparoscopic Versus Open Hemihepatectomy: The ORANGE II PLUS Multicenter Randomized Controlled Trial.
    J Clin Oncol. 2024;42:1799-1809.
    PubMed     Abstract available
    
    
    April 2024
23. CHAVEZ-VILLA M, Ruffolo LI, Line PD, Dueland S, et al
    Emerging Role of Liver Transplantation for Unresectable Colorectal Liver Metastases.
    J Clin Oncol. 2024;42:1098-1101.
    PubMed    
    
    
    March 2024
24. GORDAN JD, Kennedy EB, Abou-Alfa GK, Beal E, et al
    Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
    J Clin Oncol. 2024 Mar 19:JCO2302745. doi: 10.1200/JCO.23.02745.
    PubMed     Abstract available
    
    
    January 2024
25. HUANG DQ, Hoang JK, Kamal R, Tsai PC, et al
    Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma.
    J Clin Oncol. 2024 Jan 4:JCO2300757. doi: 10.1200/JCO.23.00757.
    PubMed     Abstract available
    
    
    November 2023
26. WANG G, Zhuo N, Liu Z
    Nonalcoholic Fatty Liver Disease May Be an Independent, Modifiable Risk Factor for Young-Onset Digestive Tract Cancers.
    J Clin Oncol. 2023;41:5070.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum